Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2024 - 2026)

Silence Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $115.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 37.87% year-over-year to $115.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $558.6 million (up 43.99% YoY) and the FY2025 annual result came in at $131.4 million, down 35.13% from the prior year.
• Liabilities and Shareholders Equity retreated to $115.1 million in Q1 2026 per SLN's latest filing, from $131.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $202.6 million in Q4 2024 and troughed at $115.1 million in Q1 2026.
• A 3-year average of $157.8 million and a median of $156.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 35.13% in 2025, then sank 37.87% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $202.6 million in 2024, then tumbled by 35.13% to $131.4 million in 2025, then dropped by 12.42% to $115.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $115.1 million, $131.4 million, and $146.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.